MORGAN STANLEY: Here are the 10 healthcare companies most likely to get bought this year by Lydia Ramsey on Feb 1, 2018, 11:31 AM Advertisement
 It's shaping up to be a big year for healthcare M&A. In the month of January alone, there was a total of $27.5 billion worth of deals, including a $9 billion deal for a cancer drugmaker and a bidding war for a Belgian biotech. US tax reform has freed up a lot of cash companies had overseas — cash that might be spent on more acquisitions to boost their businesses. While it's easy to determine who might be in the mood to do some acquiring, spotting the targets can be a bit more difficult. To help out, Morgan Stanley compiled a list of large and liquid companies it thinks will get at least one tender offer over the next 12 months. While the Morgan Stanley note contained 21 companies, we stuck to just the top 10 by market cap and trading volume. SEE ALSO: The biopharma companies that could be getting ready to spend big following tax reform Mylan  Ticker: MYL Company summary: Mylan, known for its generic drug business and as the maker of the EpiPen, got a boost in October 2017 when the FDA approved its generic version of the multiple sclerosis drug Copaxone. Market cap: $22.7 billion
Iqvia Holdings  Ticker: IQV Company summary: Iqvia, formerly known as Quintiles IMS Holdings, does both clinical trials for pharmaceutical companies and analyzes industry data. It's one of the largest contract research organizations, companies that have been going through a lot of M&A. Market cap: $23.1 billion
Edwards Lifesciences  Ticker: EW Company summary: Edwards Lifesciences is a medical device company that makes heart valves and other devices used in surgical procedures. Market cap: $23.8 billion
See the rest of the story at Business Insider
| 
0 comments:
Post a Comment